d'Almeida Sènan M, Kauffenstein Gilles, Roy Charlotte, Basset Laetitia, Papargyris Loukas, Henrion Daniel, Catros Véronique, Ifrah Norbert, Descamps Philippe, Croue Anne, Jeannin Pascale, Grégoire Marc, Delneste Yves, Tabiasco Julie
CRCNA, INSERM, CNRS, Université de Nantes, Université d'Angers, Angers, France; LabEx ImmunoGraftOnco, Angers, France; Equipe labellisée Ligue contre le Cancer, Angers, France.
BNMI, INSERM, CNRS, Université d'Angers , Angers, France.
Oncoimmunology. 2016 Apr 28;5(7):e1178025. doi: 10.1080/2162402X.2016.1178025. eCollection 2016 Jul.
Tumor-associated macrophages (TAM) are immunosuppressive cells that can massively accumulate in the tumor microenvironment. In patients with ovarian cancer, their density is correlated with poor prognosis. Targeting mediators that control the generation or the differentiation of immunoregulatory macrophages represents a therapeutic challenge to overcome tumor-associated immunosuppression. The ectonucleotidase CD39 hydrolyzes ATP into extracellular adenosine that exhibits potent immunosuppressive properties when signaling through the A2A adenosine receptor. We report here that CD14(+) CD163(+) TAM isolated from ovarian cancer patients and macrophages generated in vitro with M-CSF, express high levels of the membrane ectonucleotidase CD39 compared to classically activated macrophages. The CD39 inhibitor POM-1 and adenosine deaminase (ADA) diminished some of the immunosuppressive functions of CD14(high) CD163(high) CD39(high) macrophages, such as IL-10 secretion. We identified the cytokine IL-27, secreted by tumor-infiltrating neutrophils, located close to infiltrating CD163(+) macrophages, as a major rheostat of CD39 expression and consequently, on the acquisition of immunoregulatory properties by macrophages. Accordingly, the depletion of IL-27 downregulated CD39 and PD-L1 expression as well as IL-10 secretion by M-CSF-macrophages. Collectively, these data suggest that CD39, drived by IL-27 and CD115 ligands in ovarian cancer, maintains the immunosuppressive phenotype of TAM. This work brings new information on the acquisition of immunosuppressive properties by tumor-infiltrating macrophages.
肿瘤相关巨噬细胞(TAM)是可在肿瘤微环境中大量聚集的免疫抑制细胞。在卵巢癌患者中,它们的密度与预后不良相关。靶向控制免疫调节性巨噬细胞生成或分化的介质是克服肿瘤相关免疫抑制的一项治疗挑战。胞外核苷酸酶CD39将ATP水解为细胞外腺苷,当通过A2A腺苷受体发出信号时,腺苷具有强大的免疫抑制特性。我们在此报告,从卵巢癌患者中分离出的CD14(+)CD163(+)TAM以及体外使用M-CSF生成的巨噬细胞,与经典激活的巨噬细胞相比,表达高水平的膜胞外核苷酸酶CD39。CD39抑制剂POM-1和腺苷脱氨酶(ADA)减弱了CD14(高)CD163(高)CD39(高)巨噬细胞的一些免疫抑制功能,如IL-10分泌。我们确定肿瘤浸润性中性粒细胞分泌的细胞因子IL-27是CD39表达的主要调节因子,因此也是巨噬细胞获得免疫调节特性的主要调节因子,这些中性粒细胞靠近浸润的CD163(+)巨噬细胞。相应地,IL-27的缺失下调了M-CSF巨噬细胞的CD39和PD-L1表达以及IL-10分泌。总体而言,这些数据表明,在卵巢癌中由IL-27和CD115配体驱动的CD39维持了TAM的免疫抑制表型。这项工作为肿瘤浸润性巨噬细胞获得免疫抑制特性带来了新信息。